UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported) December 14,
2007
A.P.
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-16109
|
94-2875566
|
|
(State
or other jurisdiction
|
(Commission
|
(I.R.S.
Employer
|
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
|
123
Saginaw Drive
|
||
|
Redwood
City CA
|
94063
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code (650)
366-2626
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
INFORMATION
TO BE INCLUDED IN THE REPORT
ITEM:
8.01 Results of Shareholder meeting
A.P.
Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceuticals company, today announced
the results of a special meeting of stockholders held December 14,
2007. Stockholders approved both items under consideration at the
special meeting: 1) the adoption of the Company’s 2007 Equity Incentive Plan
comprising 3,000,000 shares of A.P. Pharma common stock reserved for issuance
under the Plan, and 2) an amendment to the Company’s 1997 Employee Stock
Purchase Plan (ESPP) to increase by 100,000 the number of shares of common
stock
reserved for issuance under the ESPP.
The
Company also announced it has made an option grant for 30,000 shares at an
exercise price of $1.70 (the closing price as of the date of the grant) to
a new
employee, as an inducement to the individual entering into employment with
the
company, under the 2000 Non-Qualified Stock Option Plan.. The options have
a 10
year life and vest over a four year period.
The
information in this Current Report on Form 8-K, including the exhibit, is
furnished pursuant to Item 8.01 and shall not be deemed "filed" for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities under that Section. Furthermore, the
information in the Current Report on Form 8-K, including the exhibit, shall
not
be deemed to be incorporated by reference into the filings of the Company under
the Securities Act of 1933, as amended.
ITEM
8.01 Press Release
(C)
Exhibits
99.1
Press release dated December 14, 2007.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
A.P.
Pharma, Inc.
|
||
|
Date:
December14, 2007
|
/S/
Michael O’Connell
|
|
|
Michael
O’Connell
|
||
|
Chief
Financial Officer and Chief Operating
Officer
|
EXHIBIT
INDEX
99.1 Press
release dated December 14, 2007
News
Release
A.P.
PHARMA STOCKHOLDERS APPROVE 2007 EQUITY INCENTIVE PLAN AND AMENDMENT TO 1997
EMPLOYEE STOCK PURCHASE PLAN
Company
Also Makes Option Grant Under 2000 Stock Option Plan
REDWOOD
CITY, Calif. (December 14, 2007) – A.P. Pharma, Inc. (NASDAQ:APPA), a
specialty pharmaceuticals company, today announced the results of a special
meeting of stockholders held December 14, 2007. Stockholders approved
both items under consideration at the special meeting: 1) the adoption of the
Company’s 2007 Equity Incentive Plan comprising 3,000,000 shares of A.P. Pharma
common stock reserved for issuance under the Plan, and 2) an amendment to the
Company’s 1997 Employee Stock Purchase Plan (ESPP) to increase by 100,000 the
number of shares of common stock reserved for issuance under the
ESPP.
The
Company also announced it has made an option grant for 30,000 shares at an
exercise price of $1.70 (the closing price as of the date of the grant) to
a new
employee, as an inducement to the individual entering into employment with
the
company, under the 2000 Non-Qualified Stock Option Plan.. The options have
a 10
year life and vest over a four year period.
About
A.P. Pharma
A.P.
Pharma is a specialty pharmaceutical company focused on the development of
ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based
drug delivery systems. The Company's primary focus is the development and
commercialization of its bioerodible injectable and implantable systems under
the trade name Biochronomer™. Initial target areas of application for the
Company's drug delivery technology include anti-nausea, pain management,
anti-inflammation and DNA/RNAI applications. For further information visit
the
Company's web site at www.appharma.com.
|
Investor
Relations Contacts:
|
Company
Contacts:
|
|
Lippert/Heilshorn
& Associates
|
Gregory
Turnbull
|
|
Don
Markley (dmarkley@lhai.com)
|
President
and Chief Executive Officer
|
|
(310)
691-7100
|
(650)
366-2626
|
|
Michael
O’Connell
|
|
|
Chief
Financial Officer and
|
|
|
Chief
Operating Officer
|
|
|
(650)
366-2626
|